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SUMMARY: Previous studies suggested the expression of mRNA, coding for CNP, exclusively in the central nervous 
system. In the present study, using the polymerase chain reaction (PCR) technique instead of the less sensitive Northern 
blot hybridization, CNP-specific sequences have also been detected in rat atria and ventricles of the heart as well as in 
organs of the immune system (thymus, spleen and lymph nodes). Parallel PCR-assays documented ANP-mRNA in these 
tissues. To verify specificity of the PCR-products, Southern blots have been hybridized with a third internal oligonucleotide 
and amplicification products have been sequenced. The relative level of CNP-mRNA in these tissues was estimated to be in 
the range of l-9% of total brain CNP transcripts. The results suggest that the peptide may have a peripheral as well as a 
central site of action. In light of its pronounced effect on cell proliferation, particular interest should focus on a possible 
role of CNP in the immune system. 
INTRODUCTION 
C-type natriuretic peptide (CNP), a new member of the 
natriuretic peptide family (1) shows features distinct from 
ANP and BNP, as CNP-mRNA expression has been 
restricted to the central nervous system (2). Furthermore, 
CNP selectively binds to the B-subtype of natriuretic 
peptide receptors which was reported to be mainly 
expressed in the brain (3). Accordingly, a central site of 
action for this peptide has been suggested (2,3). 
Recently, however, by means of the PCR-technique the B- 
tvoe receotor transcript has been detected in the periphery 
#,5), proposing the presence of the corresponding ligand, 
CNP, as well as a functional role of this peptide in 
peripheral organs. Indeed, a most recent report 
communicates the presence of CNP in cultured endothelial 
cells (6). 
The aim of the present study was to investigate the 
expression of mRNA coding for CNP in peripheral tissues 
by use of the highly sensitive PCR-technique. Emphasis 
was put on cardiac tissues, which are known to be the 
main site of synthesis for ANP and BNP, and on organs of 
the immune system, knowing that ANP, a member of the 
natriuretic peptides, is expressed in certain 
immunocompetent cells (7,8). 
MATERIALS AND METHODS 
mRNA extraction: Total RNA from rat tissues (Sprague 
Dawley, male, lOO-1209, n=3) was extracted using the 
guanidinium thiocyanate-CsC12 technique. The integrity of 
the RNA preparation was assessed by gel electrophoresis. 
and mRNA was isolated subsequently by use of a kit 
(PolyATtract, Promega, FRG). mRNA was estimated by UV 
adsorbance and additionally quantified by dot blot 
hybridization to end-labelled p(dT)12-18 according to (9). 
cDNA svnthesis: 1 mg mRNA was employed for reverse 
transcriptase reaction, using p(dT)12-l and avian 
myeloblastosis virus reverse transcriptase B-J romega, RT- 
system kit). 
PCR amolification of ANP- and CNP transcripts: PCR for 
ANP was conducted as previosly described (9). Briefly, 
various amounts of cDNA were added to 700 ng each of 
sense primer (5’-CAGCATGGGCTCCTTCTCCA-3’) and 
antisense orimer (5’-GTCAATCCTACCCCCGAAGCAGCT- 
3’) corresponding‘to the first and second exon of the rat 
ANP gene (IO). 25-40 cycles of PCR amplification, using 
2.5 units of Taq DNA polymerase (Boehringer, Mannheim, 
FRG), were performed. Amplification products (430 bp) 
were separated by gel electrophoresis (2.5% agarose), 
stained by ethidium bromide, visualized under UV and 
blotted to nylon membranes (Hybw-N, Amersham, FRG). 
An end-labelled oligonucleotide k P-ATP 5000 i/mmol, 
T4-polynucleotide kinase) corresponding t f  coding 
sequences located between the two PCR primers 
f5’-CTGCTAGACCACCTGGAGGAG-3’) was used for 
hybridization. 
Amplification and identification of CNP sequences were 
conducted as decribed for ANP. exceot for the use of the 
primers VOOng, each):’ ’ (5’- 
CGCACCATGCACCTCTCCCAGCTGAaT-3’) ‘ae,ndSean anti- 
sense orimer /5’-CGCTGCACTAACATCCCAGACCGC-3’) 
corresponding &J sequences in the first and second exon 
of the rat CNP gene (2) were used. The 553 bp comprising 
CNP amplification products were analysed as described 
above. For hybridization, a noncoding primer located in the 
second exon (5’-ATGGAGCCGATCCGGTCCAGCTT-3’) 
was employed. 
Three different mRNA samoles of each tissue were 
employed and PCR amplification of each sample was 
conducted at least twice. For both amplification procedures 
and each tissue sample various initial amounts of cDNA 
templates and numbers of PCR cycles were tested to 
ensure exponential amplification of the fragments of 
interest. 
Semiauantification of PCR-Droducts: Estimation of CNP- as 
well as ANP-mRNA tissue levels was conducted by 
densitometry of the corresponding hybridization bands 
(11). The values for either brain (CNP)- or atria (ANP) 
amplification products were assigned to an arbitrary unit of 
100. Densitometry values are presented as percentage. 
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Sequencing of CNP-transcripts: PCR products from the 
various tissues were sequenced directly on an automated 
system using Taq DNA polymerase and fluorescence 
labelled dideoxynucleotides. Sequencing was done at least 
once in each direction as described (12). 
RESULTS 
Amolification of CNP-sequences in the heart and immune 
OraanS 
cDNA samples corresponding to 0.550 ng total mRNA 
from ventricular and atrial tissues were subjected to 30 
PCR cycles. Rat genomic DNA as well as cDNA from rat 
brain were employed as positive controls for the expected 
824 bp and 554 bp comprising amplification products. 
cDNA (50 ng mRNA) from liver, which has been reported to 
express neither ANP nor BNP (9) and omission of cDNA, 
respectively, were employed to control for nonspecific 
amplification. To further support the CNP-specificity of the 
PCR-products, SoutheB blots were carried out by 
hybridization with a -P-end-labelled oligonucleotide, 
which corresponds to a cDNA sequence located between 
the two PCR-primers. As shown in Fig. lA, ventricular and 
atrial tissues express CNP-sequences comigrating with the 
CNP-amplification product from brain. Moreover, cDNA 
(corresponding to 2.550 ng mRNA) from thymus, spleen 
and lymph nodes also yield the CNP-specific 554 bp 
amplification product. For comparison, Fig. IB shows the 
expression of ANP-mRNA in the corresponding RNA 
samples. As expected, atria and ventricles show strong 
signals for the ANP transcript (430 bp). ANP-mRNA was 
also detected in the brain and the immune organs 
confirming previous reports (7,8, 13-15). 
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mre 1: Representative Southern blot of CNP-PCR 
products (A) and ANP-PCR products (B). Various amounts 
of poly(A)+ RNAs (ng) were amplified by PCR (30 cycles) 
and analysed as described in Materials and Methods. 
Lanes: 1, no cDNA; 2, rat genomic DNA; 3, liver; 4+5, 
brain; 6+7, thymus; 8+9 lymph node, lot 11, spleen; 
12 t 13, ventricle; 14 t 15, atria. 
Seauencina of CNP-amplification products 
To verify the CNP-specificity of the amplification products, 
an aliquot thereof was sequenced using the same set of 
primers (12). The sequence was virtually identical to the 
corresponding DNA sequence of the rat CNP-gene (2) 
(data not shown). 
Relative auantification of PCR amplification oroducts 
The densitometric evaluation of the CNP amplification 
products is presented as percentage of the brain value 
(Fig. 2). The signal for CNP mRNA is clearly strongest in 
the brain, confirming the predominant central expressron of 
the peptrde (1,2). However, atria and ventricle also contain 
CNP-specific PCR-products in the range of 5-9 % of the 
brain. CNP-products of the thymus, spleen and lymph 
nodes amount to approximately l-5% of that of the brain 
(Fig. 2). 
In contrast, it is well known that ANP is mainly synthesized 
in the heart atria and to a substantial amount in the 
ventricles (i.e. approximately 6% of the atrial PCR 
transcripts). The amount of PCR-generated ANP- 
sequences in the brain and the lymphoid organs were 
estimated to range between 0.02% and 1% of the atrial 
products (data not shown). 
atria ventricles spleen lymph thymus 
nodes 
Fiaure 2: Relative quantification of CNP-mRNA in various 
tissues. The values for each organ are expressed as 
percentage of the brain value and represent the 
mean C+ SEM) of three independent mRNA preparations of 
each organ and two PCR runs. 
DISCUSSION 
CNP-specific mRNA in mammals has been detected in the 
central nervous system. Thus, CNP was originally thought 
to represent the brain form of the natriuretic peptide family 
(l-3). 
However, we report here CNP-specific amplification 
products in peripheral tissues, such as the heart atria and 
ventricles as well as in organs of the immune s 
8 
stem, using 
the highly sensitive PCR technique. The P R products 
have been sequenced in order to verify the corresponding 
sequence of the CNP-gene (2,12). Semiquantitative 
comparison of CNP-expression in these tissues reveal that 
atrial and ventricular mRNA coding for CNP ranges 
between 5-9% of that in the brain. PCR products in thymus, 
spleen and lymph nodes amount to approximately l-5% of 
those obtained from the brain. Thus, our data confirm the 
predominant central expression of CNP, but provide strong 
evidence that CNP-mRNA is not restricted to the CNS, as 
originally proposed (i-3). 
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The oresence of CNP-mRNA in peripheral tissues has 
actually been postulated before (4,5j, but failed to be 
detected bv conventional mRNA analvsis (2.16). This 
proposal was based on various experimental findings, such 
as the GNP-specific B-receptor. This receptor, initially 
believed to be confined to the central nervous system (3), 
has also been found in the periphery by means of PCR 
analysis as well as by autoradiographic visualisation (45, 
17). Secondly, small amounts of immunoreactive CNP-like 
peptide were found by radioimmunoassay in the kidney 
and- intestine (181. and most recentlv also in cultured 
epithelial cells ‘(6): No material was deported for other 
peripheral tissues including the heart ventricles (18). 
Based on the predominant central site of synthesis of CNP, 
as compared to ANP/BNP, the peptide was suggested to 
act as a neurotransmitter or neuromodulator rather than a 
cardiac hormone (I-5, 19). Pharmacological actions 
distinct from those of ANP and BNP have been proposed 
for CNP. as it has been shown to stimulate water intake in 
r&contrasting the action of ANP (19). 
Our data, however, suggest that the action of CNP is not 
confined to the central nervous system With respect to the 
presence of CNP production in the immune system, 
particular interest should be focused on its pronounced 
antimitogenic and antiproliferative effect, initially observed 
in cultered smooth muscle cells (20). CNP may function in 
the regulation of cell proliferation within the immune 
system. The peptide may constitute a further substance 
shared by the neuroendocrine- and the immune system 
supporting the notion of a functional interaction between 
both systems (21). 
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